Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare Presentations of Differentiated Thyroid Cancer Exposing Dr Jekyll and Mr Hyde Nature of an Otherwise Indolent Disease: Case Series.

Clinical nuclear medicine·2024
Same author

Parathyroid Cancer Causing Acute Severe Pancreatitis.

The Journal of the Association of Physicians of India·2019
Same author

Cellular and molecular mechanisms of curcumin in prevention and treatment of disease.

Critical reviews in food science and nutrition·2019
Same author

Audit of stored strain energy and extent of future earthquake rupture in central Himalaya.

Scientific reports·2018
Same author

Reply.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2018
Same author

Indeterminate Thyroid Nodule: Mystery Continues Despite Recent Advances.

Indian journal of endocrinology and metabolism·2018

Related Experiment Video

Updated: May 9, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

The first approved agent in the Glitazar's Class: Saroglitazar.

Ritesh Agrawal1

  • 1Department of Chemistry, Shrimant Madhavrao Scindia, Government Model Science College, Jhansi Road, Gwalior, Madhya Pradesh, PIN No. 474001, India. riteshagrawalip@gmail.com.

Current Drug Targets
|August 3, 2013
PubMed
Summary

Saroglitazar, marketed as Lipaglyn, is a novel antidiabetic drug approved for Type II diabetes and diabetic dyslipidemia. This indigenously developed medication offers once-daily oral therapy, effectively managing both lipid and glycemic parameters.

Related Experiment Videos

Last Updated: May 9, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Endocrinology

Background:

  • Type II diabetes and diabetic dyslipidemia present significant global health challenges.
  • Novel therapeutic agents are crucial for improving patient outcomes.
  • Saroglitazar represents a new chemical entity (NCE) developed for diabetes management.

Purpose of the Study:

  • To describe the novel antidiabetic agent Saroglitazar.
  • To detail its chemical synthesis and patent status.
  • To summarize clinical studies evaluating its efficacy and safety.

Main Methods:

  • Review of chemical synthesis pathways for Saroglitazar.
  • Analysis of patent landscape for Saroglitazar.
  • Compilation and summary of data from clinical trials on Saroglitazar.

Main Results:

  • Saroglitazar (Lipaglyn) is an indigenously developed NCE approved in India.
  • It is indicated for Type II diabetes and diabetic dyslipidemia.
  • Clinical studies demonstrate Saroglitazar's ability to regulate lipid parameters and glycemic control.

Conclusions:

  • Saroglitazar is a significant advancement in antidiabetic therapy.
  • It offers a once-daily oral treatment option for patients with Type II diabetes and dyslipidemia.
  • The drug's development highlights Indian pharmaceutical innovation.